/
Respiratory
Interstitial Lung Disease
31
Pipeline Programs↗
56
Active Trials↗
22
Companies Involved↗
Interstitial Lung Disease is a moderately active landscape with 31 programs across 22 companies. The most active players are Luye Pharma Group Ltd., Sunshine Lake Pharma Co., Ltd., aTyr Pharma, Inc.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 13
Phase 212
Phase 34
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
25 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 94% of 31 pipeline programs.
Analysis
Trial Status
119
clinical trials
Completed40 · 34%
Recruiting29 · 24%
Not yet recruiting18 · 15%
Unknown status10 · 8%
Active, not recruiting7 · 6%
Terminated7 · 6%
Other8 · 7%
Clinical Trials
Trial Activity
119 trials
Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
Recruiting·National Institute of Environmental Health Sciences (NIEHS)·Phase 2·NCT06325696·37 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)